Covaxin: Bharat Bio gets approval for phase-III trials

Our Bureau New Delhi | Updated on October 20, 2020

Bharat Biotech’s Covid-19 vaccine Covaxin has received nod for carrying out phase-III clinical trials from drugs regulatory authorities, reliable sources said here on Tuesday.

The Subject Expert Committee on Covid-19 at the Central Drugs Standard Control Organisation (CDSCO) met here on Tuesday.

The Hyderabad-based Bharat Biotech worked with the Indian Council of Medical Research to develop Covaxin. Recently, the drug regulators allowed the firm to cut down the number volunteers to be used for the vaccine’s phase-II clinical trials as its immunogenicity results in phase-I trials were found to be very good, according to the sources.

Bharat Biotech, Zydus Cadila and Serum Institute of India are some of the frontrunners in Covid-19 vaccine development in India.

Published on October 20, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like